ACG Central Texas Lunch featuring Maria Zannes, CEO of bioAffinity Technologies, Inc.
May 23, 2017 @ 11:30 am-1:00 pm
Online registration is now open and the RSVP deadline is Fri. May 19th. ACG Member price: $30./Non-ACG Member price: $55. until the RSVP deadline. Prices increase $10 each after the RSVP deadline.
Maria Zannes brings more than 30 years of executive-level management experience dedicated to defining and advancing company goals and overcoming obstacles impeding corporate success. She was instrumental in securing significant public funding for private research into lung cancer, including the approval for a clinical trial of bioAffinity’s early lung cancer diagnostic assay. Her experience on Capitol Hill and as a lobbyist in more than a dozen state legislatures, including her prior positions as President of the Energy Recovery Council, the national trade group for the $10 billion waste-to-energy industry, and as a legislative aide specializing in energy policy and law for Congressman Charles Wilson (D-TX), provides Ms. Zannes with an appreciation of how industry can leverage government programs to advance new technologies. She was General Manager of ECOS Corporation and was responsible for the formation and development of the company that later became a subsidiary of Burlington Environmental. Ms. Zannes began her career as a journalist and is licensed to practice law in New Mexico and is a non-practicing member of the Washington State Bar. She has been awarded the Lifetime Achievement Award by the American Society of Mechanical Engineers and the Earth Engineering Center Award of Columbia University. She continues to serve as a research associate with Columbia University Earth Engineering Center and is the co-founder of two engineering research centers at the university. Ms. Zannes received her B.A. in Journalism from the University of New Mexico and her J.D. from the University of Puget Sound in Washington State.
bioAffinity Technologies, Inc. is a privately held developmental-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The Company’s platform technology will be developed to diagnose, monitor, and treat many cancers. CyPath® Lung, bioAffinity Technologies’ initial product, is designed to be the first successful non-invasive, early-stage lung cancer diagnostic on the market.
The Plaza Club100 West Houston Street, 21st Floor
San Antonio, TX78205 United States